Denileukin diftitox, also known as Ontak, is a cancer medicine used to treat certain types of T-cell lymphoma. It is a type of targeted therapy, which means it works by targeting and attacking cancer cells while leaving healthy cells alone. Denileukin diftitox is given as an intravenous (IV) infusion, usually every other day for five days. Common side effects include nausea, vomiting, fever, chills, fatigue, and low blood pressure.
Denileukin diftitox, also known by the brand name Ontak®, was a medication used to treat a specific type of cancer. Here's a breakdown of its key features:
Type of Drug: Denileukin diftitox was an antineoplastic agent, which means it targeted and destroyed cancer cells.
Mechanism of Action: It was a unique engineered protein combining two parts:
- Interleukin-2 (IL-2): This is a molecule that normally helps activate the immune system.
- Diphtheria Toxin Fragments: These fragments, once inside a cell, can disrupt protein synthesis and lead to cell death.
Denileukin diftitox worked by exploiting a weakness in some cancer cells. These cells have receptors for IL-2 on their surface. When denileukin diftitox binds to these receptors, the whole protein gets taken up by the cancer cell. Inside the cell, the diphtheria toxin fragments do their job, killing the cancer cell.
Applications: Denileukin diftitox was specifically approved for treating a type of skin cancer called cutaneous T-cell lymphoma (CTCL). This cancer affects the T-cells (immune system cells) that reside in the skin. However, it was only used for CTCL that expressed the CD25 component of the IL-2 receptor, meaning the cancer cells had the specific receptor that denileukin diftitox could target.
Withdrawal from Market: Denileukin diftitox is no longer commercially available. While it could be effective for some patients with CTCL, it also had significant side effects, and other treatment options have emerged that are often preferred.
Here are some additional points to consider:
- Denileukin diftitox was administered intravenously (through a vein).
- Common side effects could include capillary leak syndrome (feeling weak and lightheaded), rash, fever, and nausea.
- Due to its withdrawal from the market, it's unlikely to be a treatment option considered by doctors for new CTCL cases.
If you have any further questions about CTCL or its treatment options, consult a healthcare professional.